Converging evidence from basic and clinical studies suggests a role for proinflammatory cytokines in cancer-related fatigue, although the etiology of elevated inflammatory processes is unclear. We examined single nucleotide polymorphisms (SNPs) in the promoters of cytokine genes as genetic risk factors for cytokine-related fatigue in 33 fatigued and 14 non-fatigued breast cancer survivors, focusing on promoter sequence polymorphisms in IL1B and IL6 associated with differential expression of proinflammatory cytokines. Predictors of fatigue included presence of at least one cytosine at IL1B À511 (95%CI = 0.91-16.6, p = .007) and homozyosity for either variant of the IL6 À174 genotype (G/G or C/C; 95%CI = 1.12-17.9, p = .027). Associations between fatigue status and IL1B genotype remained significant after covariate adjustment for demographic, biobehavioral and treatment-related factors. These findings provide preliminary evidence that polymorphisms in IL1B may serve as a potential risk factor for persistent fatigue in the aftermath of cancer.
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Introduction
Persistent, medically unexplained fatigue is one of the most common and disabling sequelae of breast cancer treatment (Bower et al., 2000 (Bower et al., , 2006 . Experimental studies documenting effects of proinflammatory cytokines on central nervous system function and ''sickness behavior" (Dantzer et al., 2008; Kent et al., 1992) have led our group and others to examine proinflammatory cytokine activity as a potential mechanism for cancer-related fatigue. We have shown elevations in plasma and cellular markers of inflammation in breast cancer survivors with persistent post-treatment fatigue, including elevations in circulating levels of IL-1 receptor antagonist (IL-1ra) and soluble IL-6 receptor (sIL-6r) as well as increases in ex vivo monocyte production of IL-6 following LPS stimulation (Bower et al., 2002 (Bower et al., , 2003 (Bower et al., , 2007 Collado-Hidalgo et al., 2006) . However, the etiology of chronic inflammatory processes and associated symptoms of fatigue has not been determined.
The present study was designed to test the hypothesis that variations in cytokine-related fatigue are influenced by genetic polymorphisms in the regulatory regions (promoters) of genes that encode proinflammatory cytokines. In particular, we focus on genes related to the proinflammatory cytokines IL-1b and IL-6, given evidence of alterations in these systems among fatigued breast cancer survivors (Bower et al., 2002 (Bower et al., , 2003 (Bower et al., , 2007 Collado-Hidalgo et al., 2006) and other cancer populations with fatigue (Schubert et al., 2007) . Single nucleotide polymorphisms (SNPs) that influence quantitative gene expression levels have been identified in the promoters of IL1B (À511 bases upstream of the transcription start site) (Giovine et al., 1992) and IL6 (À174) (Fishman et al., 1998; Olomolaiye et al., 1998) . Recent evidence suggests a relationship between promoter polymorphisms in several proinflammatory cytokine genes and breast cancer susceptibility and prognosis (Hefler et al., 2005; Smith et al., 2004) , as well as treatment-related changes in breast appearance (Andreassen et al., 2005) . However, links with behavioral symptoms have not yet been examined. Based on the a priori hypothesis that polymorphisms affecting proinflammatory cytokine levels should influence the risk of fatigue, we tested promoter polymorphisms in IL1B and IL6 as candidate genes for fatigue in breast cancer survivors.
